ANIX (Anixa Biosciences) Pretax Margin %: % (As of Apr. 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.64
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Pretax Margin %?

Anixa Biosciences ANIX -2.60% 27 Pretax Margin % is % as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Anixa Biosciences ranks worse than 105708.14% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Anixa Biosciences's Pre-Tax Income for the three months ended in Apr. 2026 was $-2.54 Mil. Anixa Biosciences's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Therefore, Anixa Biosciences's pretax margin for the quarter that ended in Apr. 2026 was %.

The historical rank and industry rank for Anixa Biosciences's Pretax Margin % or its related term are showing as below:


ANIX's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Anixa Biosciences  (NAS:ANIX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Anixa Biosciences Pretax Margin % Related Terms


Anixa Biosciences Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Pretax Margin % Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,564.06 0.00 -4,728.57 0.00 0.00

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANIX vs PYPD, LONA, SGMO: Pretax Margin % Comparison

For the Biotechnology subindustry, Anixa Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Pretax Margin % falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Anixa Biosciences's Pretax Margin for the fiscal year that ended in Oct. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Oct. 2025 )/Revenue (A: Oct. 2025 )
=-11.028/0
= %

Anixa Biosciences's Pretax Margin for the quarter that ended in Apr. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-2.536/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Anixa Biosciences (ANIX) has a Pretax Margin % of % as of Apr. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #999999 out of 946 companies in the Biotechnology industry.
Is Anixa Biosciences' Pretax Margin % too high?
Anixa Biosciences' current Pretax Margin % is %. Based on the distribution chart, Anixa Biosciences ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Pretax Margin % compare to PYPD and LONA?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #999999 out of 946 companies for Pretax Margin %. This places Anixa Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Pretax Margin % of %. The current Pretax Margin % is %. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Pretax Margin % is % as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.64
Price